TREA

98479628 - PELLMOFI

Follow

Information

  • Trademark
  • 98479628
  • Serial Number
    98479628
  • Filing Date
    April 02, 2024
    a year ago
  • Transaction Date
    May 14, 2025
    19 days ago
  • Status Date
    May 06, 2025
    27 days ago
  • Published for Opposition Date
    May 06, 2025
    27 days ago
  • Location Date
    April 17, 2025
    a month ago
  • Status Code
    686
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    CAPSHAW, DANIEL
  • Attorney Name
    Maury M. Tepper, III
    Law Office Assigned Location Code
    M10
  • Owners
Information
Mark Drawing Code
4
Mark Identification
PELLMOFI
Case File Statements
  • GS0051: Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of blood diseases; pharmaceutical preparations for the treatment of diseases of the bone marrow; pharmaceutical preparations for the treatment of cancer, namely, BET protein inhibitors; pharmaceutical preparations for the treatment of myelofibrosis; pharmaceutical preparation for the treatment of myelodysplastic syndrome (MDS); pharmaceutical preparations for the treatment of myeloproliferative neoplasm; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the treatment of thrombocythemia; pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics; pharmaceutical preparations comprising small molecules for treating cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; small molecule pharmaceuticals for the treatment of diseases and conditions, namely cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; pharmaceuticals and pharmaceutical preparations for human use for the treatment and prevention of diseases and disorders, namely cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; antibodies sold as a component ingredient of pharmaceuticals for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; antibodies for use in the manufacture of active ingredients of pharmaceuticals and vaccines for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; diagnostic preparations for medical purposes; clinical medical reagents; biological preparations for medical purposes, namely for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; pharmaceutical and veterinary preparations, and agents for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways
Case File Event Statements
  • 4/2/2024 - a year ago
    1 - NEW APPLICATION ENTERED Type: NWAP
  • 4/2/2024 - a year ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 10/16/2024 - 7 months ago
    4 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 10/16/2024 - 7 months ago
    6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 10/15/2024 - 7 months ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 10/16/2024 - 7 months ago
    5 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 1/15/2025 - 4 months ago
    7 - APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED Type: XELR
  • 1/15/2025 - 4 months ago
    8 - APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED Type: XELG
  • 4/7/2025 - a month ago
    10 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 4/7/2025 - a month ago
    9 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 4/8/2025 - a month ago
    11 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 4/9/2025 - a month ago
    12 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 4/30/2025 - a month ago
    13 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 5/9/2025 - 24 days ago
    16 - TEAS CHANGE OF OWNER ADDRESS RECEIVED Type: COAR
  • 5/9/2025 - 24 days ago
    18 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP
  • 5/9/2025 - 24 days ago
    19 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA
  • 5/9/2025 - 24 days ago
    17 - APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Type: CHAN
  • 5/9/2025 - 24 days ago
    20 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA
  • 5/6/2025 - 27 days ago
    15 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 5/6/2025 - 27 days ago
    14 - PUBLISHED FOR OPPOSITION Type: PUBO